{
    "nct_id": "NCT06679985",
    "official_title": "A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma",
    "inclusion_criteria": "* Unresectable locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases criteria in cirrhotic participants.\n* Disease that is not amenable to curative surgical and/or locoregional therapies or progressive disease (PD) after surgical and/or locoregional therapies.\n* â‰¥ 1 measurable lesion (per RECIST v1.1) that is untreated.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has received prior systemic therapy for HCC.\n* Has previously received an anti-IL-27 antibody (Ab) or anti-IL-27-targeted therapy.\n* Has known fibrolamellar HCC histology, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.\n* Has moderate or severe ascites.\n* Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).\n\nAdditional protocol-defined inclusion/exclusion criteria apply.",
    "miscellaneous_criteria": "Key"
}